98 results
424B3
PASG
Passage Bio Inc
14 May 24
Prospectus supplement
8:15am
for enhanced benefits due to widespread vector delivery to the brain and spinal cord, and an improved safety profile compared with systemic administration … to widespread vector delivery to the brain and spinal cord, and an improved safety profile compared with systemic administration due to the lower doses
8-K
EX-99.2
PASG
Passage Bio Inc
14 May 24
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
7:01am
drug candidates; the occurrence of adverse safety events; the risk that positive results in a preclinical study or clinical trial may … safety and biomarker data from Cohort 1 patients Announce 12-month follow-up data from Cohort 1 patients Report initial safety and biomarker data from
8-K
EX-99.1
PASG
Passage Bio Inc
14 May 24
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
7:01am
with longest follow-up
Completed dosing of Cohort 1 (n=5) in upliFT-D trial; on track to deliver 6-month safety and biomarker data from Cohort 1 in 2H … remains on track to deliver 6-month safety and biomarker data from Cohort 1 in the second half of 2024.
Plan to continue studying Dose 1 in Cohort 2
S-3
PASG
Passage Bio Inc
4 Mar 24
Shelf registration
4:09pm
to the brain and spinal cord, and an improved safety profile compared with systemic administration due to the lower doses required.
We are currently … administration, which provides the potential for enhanced benefits due to widespread vector delivery to the brain and spinal cord, and an improved safety
8-K
EX-99.1
8gf0oe
4 Mar 24
Passage Bio Reports Fourth Quarter and Full-year 2023 Financial Results and Provides Recent Business Highlights
7:02am
8-K
EX-99.2
nxx8bc6
4 Mar 24
Passage Bio Reports Fourth Quarter and Full-year 2023 Financial Results and Provides Recent Business Highlights
7:02am
8-K
EX-99.1
429clir4pm0lucs
5 Jan 24
Regulation FD Disclosure
4:05pm
8-K
EX-99.1
fcvc2zf676j1sk2rp
20 Dec 23
Passage Bio Announces Promising Initial Data from Phase 1/2 Clinical Trial of PBFT02 In FTD-GRN and Updated Strategic Priorities
7:05am
8-K
ctj xpz20nsn8gedl
20 Dec 23
Passage Bio Announces Promising Initial Data from Phase 1/2 Clinical Trial of PBFT02 In FTD-GRN and Updated Strategic Priorities
7:05am
8-K
EX-99.1
5wv4rimwo 73
13 Nov 23
Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
7:00am
8-K
EX-99.2
pyqllib
13 Nov 23
Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
7:00am
8-K
EX-99.3
zqqu27c
7 Aug 23
Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights
7:15am
8-K
EX-99.1
f4pfy5
7 Aug 23
Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights
7:15am